News | May 04, 2026
Bristol Myers Squibb begins 2026 with growth momentum
The company’s Growth Portfolio delivered $6.2 billion in revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
Lifts full-year outlook as obesity drug boom accelerates
Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
The agreement could rise to $900 million if key commercial milestones are met
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Rs. 40 cr buyback, 200% dividend announced
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
The summit brought together over 150 doctors, researchers, and practitioners worldwide
Subscribe To Our Newsletter & Stay Updated
